{"id":"W4386570892","doi":"10.1016/j.jtocrr.2023.100572","title":"Patient-Reported Health-Related Quality of Life in KEYNOTE-604: Pembrolizumab or Placebo Added to Etoposide and Platinum as First-Line Therapy for Extensive-Stage SCLC","year":2023,"lang":"en","type":"article","venue":"JTO Clinical and Research Reports","topic":"Lung Cancer Research Studies","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"Daiichi Sankyo Europe; National Cancer Institute; Chugai Pharmaceutical; Merck Sharp and Dohme; Genentech; Oryzon Genomics; BeiGene; Merck KGaA; Gilead Sciences; GlaxoSmithKline; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Pembrolizumab; Medicine; Placebo; Internal medicine; Lung cancer; Quality of life (healthcare); Hazard ratio; Confidence interval; Etoposide; Oncology; Chemotherapy; Surgery; Cancer; Pathology; Immunotherapy; Nursing","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001146523,0.0006566772,0.001750597,0.000242279,0.0001908536,0.0005884208,0.0005247323,0.0007405307,0.005279799],"category_scores_gemma":[0.0008730836,0.0003099887,0.0007867372,0.0002657789,0.0005190878,0.0005411676,0.0004036739,0.001390559,0.0004312394],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004426001,"about_ca_system_score_gemma":0.0004980186,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003394845,"about_ca_topic_score_gemma":0.0006326627,"domain_scores_codex":[0.9995512,0.0001984479,0.00005136884,0.0000855436,0.00005446496,0.00005895288],"domain_scores_gemma":[0.9996874,0.00006296229,0.0001131339,0.00001887637,0.00001588704,0.0001018511],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8692164,0.01318064,0.003454318,0.001291882,0.0009797753,0.00006709158,0.00007551464,0.0009104497,0.03891489,0.00007972826,0.001293896,0.07053529],"study_design_scores_gemma":[0.4373004,0.5128333,0.03518197,0.0001348742,0.001399877,0.0002105897,0.00006185914,0.001222137,0.00943587,0.00015428,0.002028736,0.00003602256],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9951527,0.002748753,0.000160764,0.0001381387,0.00008773994,0.0003766213,0.0004008941,0.00004368246,0.0008907275],"genre_scores_gemma":[0.9971883,0.0008434953,0.0003203475,0.000167352,0.00006612801,0.000501235,0.0003773785,0.00000487845,0.0005310604],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005279799,"threshold_uncertainty_score":0.0176627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.3304689780494397,"score_gpt":0.5523388797000741,"score_spread":0.2218699016506344,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}